Compare Keysight Technologies Inc (KEYS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Recursion Pharmaceuticals Inc — how do they compare? Keysight Technologies Inc trades at $345.46 (market cap $57.32B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Keysight Technologies Inc is far larger — about 32.2× Recursion Pharmaceuticals Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| KEYS | RXRX | |
|---|---|---|
Market Cap | $57.32B | $1.78B |
Sector | Technology | Health |
52-Week High | $373.34 | $6.79 |
52-Week Low | $158.51 | $2.84 |
Enterprise Value | $57.67B | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $340.97, up 1.19% today, near its 52-week high. The stock shows strong momentum with bullish moving averages and consistent earnings beats, including Q1 2026 EPS of $2.87 versus $2.32 expected. Revenue for 2025 reached $5.38B with a net income margin of 17.31%. Recent news highlights product innovations like the APS-ONE-400 cybersecurity platform and collaborations with Intel and the European Space Agency, reinforcing growth prospects in 5G and defense markets.
Outlook remains positive with a consensus price target of $396.56, implying 16% upside, supported by 81% analyst buy ratings. Risks include elevated valuation multiples (P/E 54.91) and high RSI levels suggesting overbought conditions. Investors should monitor execution on 2026 revenue guidance of $6.1B and manage exposure to tech sector volatility.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
